Oruka Therapeutics SVP sells 533 shares at $95.75

Q: Who from ORKA reported this Form 4 transaction and what is their role?

The Form 4 reports a transaction by Arjun Agarwal, who is identified as Senior Vice President, Finance of Oruka Therapeutics, Inc., and therefore an officer of the company.

Q: How many ORKA shares did Arjun Agarwal sell in this Form 4?

Arjun Agarwal sold 533 shares of Oruka Therapeutics, Inc. common stock in the reported transaction on September 21, 2026.

Q: How many ORKA shares does Arjun Agarwal hold after this reported sale?

Following the sale, Arjun Agarwal is reported to hold 14,219 shares of Oruka Therapeutics, Inc. common stock directly.

Q: Is the ORKA Form 4 transaction a purchase or a sale?

The Form 4 reports a sale of Oruka Therapeutics, Inc. common stock, coded as a sale in an open-market or private transaction, with 533 shares sold.

Senior finance officer Arjun Agarwal executed a small Rule 10b5-1 planned sale of Oruka Therapeutics common stock, leaving a reported 14,219 shares held directly.

Available on EDGAR 09/21/2026 - 05:39 PM EDT Accepted by SEC EDGAR 09/21/2026 - 05:38 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) reported that Senior Vice President, Finance Arjun Agarwal sold 533 shares of common stock on September 21, 2026 at $95.75 per share in an open-market or private transaction. After this sale, he held 14,219 shares directly. The transaction was effected under a Rule 10b5-1 trading plan entered into on February 11, 2026.

Insider Trade Summary 10b5-1

Net Seller: 533 shares

Net Sell 1 txn

Insider Agarwal Arjun

Role Senior Vice President, Finance

Sold 533 shs ($51K)

Share of Position Sold 3.6%

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	533	$95.75	$51K

Holdings After Transaction: Common Stock — 14,219 shares (Direct)

Holdings Before and After: Common Stock, 14,752 to 14,219 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

Key Figures

Shares sold: 533 shares Sale price per share: $95.75 per share Shares held after transaction: 14,219 shares +1 more

4 metrics

Shares sold 533 shares Common Stock sold by Arjun Agarwal on September 21, 2026

Sale price per share $95.75 per share Price for the 533 shares of Common Stock sold on September 21, 2026

Shares held after transaction 14,219 shares Direct ownership of Oruka Therapeutics Common Stock after the reported sale

Net shares sold 533 shares Net change in buy/sell shares across all reported transactions in this Form 4

Key Terms

Rule 10b5-1 trading plan, Common Stock, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"These sales were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Common Stock financial

"security title is listed as Common Stock for the transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"described as a Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who from ORKA reported this Form 4 transaction and what is their role?

The Form 4 reports a transaction by Arjun Agarwal, who is identified as Senior Vice President, Finance of Oruka Therapeutics, Inc., and therefore an officer of the company.

How many ORKA shares did Arjun Agarwal sell in this Form 4?

Arjun Agarwal sold 533 shares of Oruka Therapeutics, Inc. common stock in the reported transaction on September 21, 2026.

At what price were the ORKA shares sold in this Form 4 transaction?

The reported sale of Oruka Therapeutics, Inc. common stock was executed at a price of $95.75 per share in an open-market or private transaction.

How many ORKA shares does Arjun Agarwal hold after this reported sale?

Following the sale, Arjun Agarwal is reported to hold 14,219 shares of Oruka Therapeutics, Inc. common stock directly.

Was the ORKA insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that these sales were effected pursuant to a Rule 10b5-1 trading plan that was entered into on February 11, 2026.

Is the ORKA Form 4 transaction a purchase or a sale?

The Form 4 reports a sale of Oruka Therapeutics, Inc. common stock, coded as a sale in an open-market or private transaction, with 533 shares sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agarwal Arjun

(Last)

(First)

(Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK

CALIFORNIA

94025

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Senior Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/21/2026		S⁽¹⁾		533	D	$95.75	14,219	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

	/s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR